Kadmon (KDMN) Given Daily News Sentiment Score of 0.16

Headlines about Kadmon (NYSE:KDMN) have been trending somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Kadmon earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.5914606778657 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern’s rankings:

KDMN has been the topic of a number of analyst reports. WBB Securities downgraded shares of Kadmon from a “hold” rating to a “sell” rating and set a $3.00 target price on the stock. in a research note on Monday, October 9th. Zacks Investment Research raised shares of Kadmon from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a research note on Friday, January 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Kadmon in a research note on Friday, November 17th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Kadmon currently has an average rating of “Hold” and a consensus target price of $8.65.

Shares of Kadmon (NYSE:KDMN) opened at $4.49 on Thursday. The stock has a market cap of $344.46, a P/E ratio of -2.57 and a beta of 2.54. Kadmon has a 52 week low of $2.05 and a 52 week high of $5.02.

Kadmon (NYSE:KDMN) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). The firm had revenue of $2.28 million for the quarter, compared to analyst estimates of $5.69 million. The business’s revenue for the quarter was down 60.0% on a year-over-year basis. During the same quarter last year, the business earned ($4.24) earnings per share. analysts anticipate that Kadmon will post -1.61 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was first reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.truebluetribune.com/2018/01/18/kadmon-kdmn-given-daily-news-sentiment-score-of-0-16.html.

About Kadmon

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Insider Buying and Selling by Quarter for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply